Detailed Narrative
Record Margins Driven by Product Mix and Efficiency
Alivus achieved a landmark EBITDA margin of 36.4% in Q3 FY26, a significant jump from previous levels. This was driven by high-margin new product launches in Europe, China, and LATAM, alongside a 100% QoQ recovery in the CDMO segment. Management also cited operational efficiencies, specifically improved yields and lower energy utilization, as sustainable contributors to this margin profile, leading to an upward revision of full-year guidance to 30-32%.
CDMO Segment Rebounds Sharply
The CDMO business saw a massive turnaround in Q3, with revenue growing 85.3% YoY. This was fueled by the ramp-up of Project 4 and the commencement of Project 5. Management expects to conclude 1-2 more projects by mid-calendar year 2026. While analysts questioned the relatively small deal sizes ($4-6 million), management defended their strategy of focusing on lifecycle management and specialty molecules where they have a higher probability of success compared to high-attrition NCE projects.
Strategic Calibration of Solapur Expansion
The Solapur facility expansion has been slightly delayed by three months and is now expected to start operations in July 2026. The initial capacity has been calibrated to 450-500 KL, down from the earlier 600 KL, to ensure high utilization and avoid under-absorption. Management emphasized that this delay does not risk growth, as brownfield expansions at Ankleshwar and Dahej are on track to provide a two-year runway for regulated markets.
Diversified Sourcing Mitigates China Risk
Despite currency headwinds where the Renminbi is strengthening against the Dollar, Alivus maintains a resilient supply chain. Sole dependency on China for raw materials is now less than 10%, and the company has a well-distributed vendor base. Management has actively worked to bring a fair amount of sourcing back to India and utilizes alternate suppliers to ensure supply security.
R&D Focus on Complexity and Flow Chemistry
R&D expenditure remained steady at 3.4% of sales for the quarter. The company is pivoting towards more complex molecules and 'flow chemistry' to drive cost leadership. One successful implementation of flow chemistry has already reduced a product's cost to 40% of its original batch-process cost. The high-potent API portfolio, consisting of 27 products, is expected to start contributing meaningfully to the topline from late FY28.